Mallinckrodt enrolls first infant in registry for inhaled nitric oxide gas

Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that it included the first patient in its Phase IV registry evaluating the use of inhaled Inomax nitric oxide gas for premature neonates compared to term and near-term newborns.

Inomax, which has FDA approval, is designed to boost oxygenation and lessen the need for extracorporeal membrane oxygenation in term and near-term neonates with hypoxic respiratory failure linked to pulmonary hypertension.

The primary outcome measure of the 168-patient registry is slated to compare the incidence of participants with at least a 25% improvement in oxygenation index or surrogate oxygenation index compared to baseline, according to gestation age group.

Mallinckrodt said it expects the observational registry will be completed by 2022.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.